2024-02-13 11:30:05 ET
More on Cytokinetics
- Cytokinetics Steps Up As Prime Target After Aficamten's HCM Triumph (Rating Upgrade)
- Cytokinetics: Clear Win For Aficamten In SEQUOIA-HCM Phase 3 Trial (Upgrade)
- Cytokinetics: Buyout Rumors Ahead Of The Key Phase 3 Readout Of Aficamten
- Cytokinetics weakness a buying opportunity, Truist says
- Biggest stock movers today: Nvidia, Air Products and Chemicals, Estee Lauder, 4D Molecular Therapeutics, and more
Read the full article on Seeking Alpha
For further details see:
Cytokinetics seesaws as CEO says not conducting a sales process